Results 51 to 60 of about 16,284 (266)

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Cerebrospinal fluid from patients with subarachnoid haemorrhage and vasospasm enhances endothelin contraction in rat cerebral arteries.

open access: yesPLoS ONE, 2015
IntroductionPrevious studies have suggested that cerebrospinal fluid from patients with subarachnoid hemorrhage (SAH) leads to pronounced vasoconstriction in isolated arteries.
Barbara Assenzio   +11 more
doaj   +1 more source

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer. [PDF]

open access: yesPLoS ONE, 2015
Endothelin A (ET-A) receptor antagonists including zibotentan and atrasentan, have been suggested as a treatment for castration-resistant prostate cancer (CRPC).
Ping Qi   +5 more
doaj   +1 more source

In‐hospital and 1 year incremental prognostic value of drug abuse detection in acute heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The study aims to assess the in‐hospital and 1 year incremental prognostic value of recent drug abuse use, detected by a systematic urinary screening, in a consecutive cohort of patients hospitalized for acute heart failure (AHF). Methods All patients admitted for AHF with a drug abuse screening using a urinary assay were included in this
Charles Fauvel   +110 more
wiley   +1 more source

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension

open access: yesDrug Design, Development and Therapy, 2009
Kari E Roberts, Ioana R PrestonPulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USAAbstract: Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH).
Kari E Roberts, Ioana R Preston
doaj  

Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor

open access: yesBMC Cancer, 2008
Background Endothelin receptor antagonists inhibit the progression of many cancers, but research into their influence on glioma has been limited. Methods We treated glioma cell lines, LN-229 and SW1088, and melanoma cell lines, A375 and WM35, with two ...
Patterson Paul H, Montgomery Jennifer P
doaj   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr   +15 more
wiley   +1 more source

Role for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients

open access: yesESC Heart Failure, EarlyView.
Abstract Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.
Abdul‐Fatawu Osman   +11 more
wiley   +1 more source

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis

open access: yesESC Heart Failure, EarlyView.
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy